Atherogenic Lipid Ratios Related to Myeloperoxidase and C-Reactive Protein Levels in Psychotic Disorders

Elina J. Reponen1*, Ingrid Dieset1,2, Martin Tesli1,3, Ragni H. Mørch1, Monica Aas1, Trude S. J. Vedal1, Elisabeth Haug4, Ole Kristian Drange5,6, Nils Eiel Steen1, Sigrun Hope1,7, Attila Szabo1, Sherif M. Gohar1,8, Kirsten Wedervang-Resell1,9, Srdjan Djurovic10,11, Ingrid Melle1, Pål Aukrust12,13,14, Ole A. Andreassen1 and Thor Ueland12,13,15

1 NORMENT Norwegian Centre for Mental Disorders Research, Oslo University Hospital and University of Oslo, Oslo, Norway, 2 Division of Mental Health and Addiction, Acute Psychiatric Department, Oslo University Hospital, Oslo, Norway, 3 Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway, 4 Department of Acute Psychiatry and Psychosis Treatment, Inntrekt Hospital Trust, Reinsvoll, Norway, 5 Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway, 6 Department of Østmarka, Division of Mental Health Care, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 7 Department of Neuro Habilitation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway, 8 Department of Psychology, Faculty of Medicine, Cairo University, Cairo, Egypt, 9 Division of Mental Health and Addiction, Department of Psychiatric Research and Development, Oslo University Hospital, Oslo, Norway, 10 Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 11 NORMENT Norwegian Centre for Mental Disorders Research, Department of Clinical Science, University of Bergen, Bergen, Norway, 12 Institute of Clinical Medicine, University of Oslo, Oslo, Norway, 13 Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, 14 Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway, 15 K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway

Background: Cardiovascular disease (CVD) is a major cause of premature death in patients with psychotic disorders, where dyslipidemia occurs frequently. In the pathogenesis of these serious mental disorders, a low-grade inflammation seems to be a possible contributor. Concurrently, systemic inflammation and its interplay with dyslipidemia is a central driver in the pathogenesis of CVD. We hypothesize that evaluation of atherogenic lipid ratios together with inflammatory markers reflecting different inflammatory pathways with relevance for atherogenesis, could give novel information on immune-related mechanisms involved in early CVD risk in patients with psychotic disorders.

Methods: As a measure for CVD risk we calculated atherogenic lipid ratios using established sex-specific cut-offs: Total cholesterol/high-density lipoprotein; HDL-c (TC/HDL) and triglyceride/HDL-c (TG/HDL) were evaluated in 571 schizophrenia (SCZ) and 247 bipolar disorder (BD) patients, and in 99 healthy controls (HC). In addition, as a measure of low-grade inflammation, we measured fasting plasma levels of nine stable atherogenic inflammatory markers in patients (SCZ, BD) and in HC. The elevated inflammatory markers and CVD risk in patients, as reflected by TC/HDL and TG/HDL, were further assessed in multivariable analyses adjusting for comorbid cardio-metabolic risk factors.
Results: A markedly higher proportion (26%–31%) of patients had increased TC/HDL and TG/HDL ratios compared with HC. Plasma levels of high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO) were higher (p<0.05, p<0.001) in patients with psychotic disorders than in HC, and hs-CRP and MPO were independently associated with atherogenic lipid ratios in the multivariable analyses.

Conclusions: Our findings suggest that low-grade inflammation and abnormal neutrophil activation may cause increased CVD risk in patients with psychotic disorders. These mechanisms should be further examined to determine the potential for development of novel risk evaluation strategies.

Keywords: CVD risk, dyslipidemia, inflammatory biomarkers, schizophrenia, bipolar disorder

INTRODUCTION

Psychotic disorders are characterized by significant comorbid cardiometabolic risk (1, 2), and cardiovascular disease (CVD) mortality is elevated in patients with psychotic disorders. Compared with the general population, the risk of cardiovascular mortality is almost 2-fold in bipolar disorder and 2 to 3-fold in schizophrenia (3–5). Undiagnosed CVD prior to cardiovascular death is more common in psychotic disorders than in the general population (6).

Furthermore, dyslipidemia has frequently been reported in patients with severe mental disorders (1, 2). It is well known that second generation antipsychotic drugs (SGA) are associated with dyslipidemia and other metabolic side effects (7), but long-term antipsychotic treatment is contrarily associated with reduced CVD mortality (8).

Atherogenic lipid ratios such as the total cholesterol/high-density lipoprotein; HDL-c (TC/HDL) and triglyceride/HDL-c (TG/HDL) have been shown to hold greater predictive value for CVD risk in individuals without symptomatic CVD than the isolated lipid parameters used independently (9, 10). Although increased TC and TG and reduced HDL-c have been reported (1, 2), these ratios have scarcely been investigated in psychiatric disorders.

It is well known that lipid accumulation together with low-grade inflammation lead to a chronic vascular remodeling and development of atherosclerosis in the arteries (11). An increasing number of novel inflammatory biomarkers that predict cardiovascular risk have recently been identified. These biomarkers are therefore relevant to investigate in patients with psychotic disorders, where a low-grade inflammation is a possible pathogenic contributor (12, 13).

Based on the emerging role of inflammation and its interaction with dyslipidemia in the progression of atherosclerotic disease, we hypothesize herein that evaluation of atherogenic lipid ratios together with inflammatory markers reflecting different inflammatory pathways with relevance for atherogenesis, could give novel information on immune-related mechanisms involved in the premature CVD risk in patients with psychotic disorders.

Our specific aims of this study were three-fold. Firstly, we evaluate whether the following inflammatory markers are dysregulated in patients with psychotic disorders versus HC:

- General down-stream markers of inflammation: High-sensitivity C-reactive protein (hs-CRP) (14) and glycoprotein 130 (gp130, a member of the interleukine-6 receptor family) (15).
- Markers of vascular inflammation, calcification, and endothelial function: Pentraxin 3 (PTX3) (16), osteoprotegerin (OPG) (17), and von Willebrand factor (vWF) (18).
- Markers related to fibrosis and extracellular matrix (ECM) remodeling: Galectin 3 (19) and Cathepsin S (20).
- Marker of neutrophil activation: Myeloperoxidase (MPO) (21).
- Marker of vascular apoptosis: Insulin-like growth factor-binding protein 4 (IGFBP4) (22).

Thirdly and lastly, we further investigate whether CVD risk as estimated by lipid ratios is associated with any upregulated inflammatory markers identified in the patient population. This study presents a detailed and thorough analysis of these three topics on a uniquely large cohort of patients with psychotic disorders.

METHODS

Design and Participants

The current study is part of the ongoing Thematically Organized Psychosis (TOP) Study at the Norwegian Centre for Mental Disorders Research (NORMENT). The TOP Study includes patients from both outpatient clinics and hospitals in the Oslo, Trondheim, and Lillehammer regions in Norway. Inclusion criteria in the TOP Study are: diagnosis of severe mental disorder, age between 18–65 years and ability to give written informed consent. The healthy controls (HC), between 18–60 years old, were randomly selected from statistical records (www.ssb.no) in the Oslo region. All participants have given informed written consent. The study was approved by the Norwegian Scientific Ethical Committees and the Norwegian Data Protection Agency.

Sample

The sample used for the current cross-sectional study consists of 818 patients with severe mental disorders and 99 healthy controls.

Sample
with fasting blood samples available, all included in the TOP Study from 2002 until 2013. In this sample, 571 patients had a schizophrenia spectrum disorder (SCZ: schizophrenia, schizoaffective disorder, schizophréniform disorder and psychotic disorder not otherwise specified), while 247 patients had a bipolar spectrum disorder (BD: bipolar I, bipolar II and bipolar disorder not otherwise specified). The SCZ and BD groups combined are hereafter referred to as the “all patients” group.

Participants with non-fasting blood samples, autoimmune or inflammatory diseases, on-going cancer, on-going infections, C-reactive protein (CRP) >20 mg/L of any reason, insulin levels >400 pmol/L, or participants receiving treatment with immune modulating drugs were excluded.

**Clinical Assessments**

All patients underwent a thorough diagnostic evaluation based on the Structured Clinical Interview in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) axis I Disorders (SCID-I). The Positive and Negative Syndrome Scale (PANSS), the Young Mania Rating scale (YMRS), and the Calgary Depression Scale for Schizophrenia (CDSS) were used for evaluations of the symptoms, and the functioning was assessed using the functioning score of the split version of the Global Assessment of the Functioning Scale (GAF-F). The inter-investigator diagnostic agreement has previously been evaluated to a satisfying level of 82%, with overall \( \kappa = 0.77 \) (CI 0.60–0.94) (23).

Body mass index (BMI) (kg/m\(^2\)) was calculated based on height and weight measured by standard methods. For weight digitally calibrated weights were used. Blood pressure was measured using a manual device under standard conditions. The HC were interviewed using the Primary Care Evaluation of Mental Disorders (PRIME MD) to assess current or previous history of severe mental disorder themselves or in their family.

**Blood Samples**

The methodology used for drawing, processing and storage of blood samples have been described previously (24). Some of these biological markers have been reported previously by us in relation to other outcome measures (25–30).

**Lipid Risk Factors**

Plasma levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-c), and low-density lipoprotein (LDL-c) were measured at the Department of Medical Biochemistry, Oslo University Hospital. TC, TG, and HDL-c were directly measured using an Integra 800 instrument from Roche Diagnostics, according to standard methods. LDL-c was calculated by Friedewald formula at the Department of Medical Biochemistry, Oslo University Hospital. This method changed during the study to direct measurement of LDL-c using an Integra 800 instrument from Roche Diagnostics.

**Inflammatory Markers**

Plasma levels of hs-CRP, gp130, PTX3, OPG, vWF, Galectin 3, Cathepsin S, MPO, and IGFBP4 were measured by enzyme immunoassays (EIA) in duplicate using commercially available antibodies (R&D Systems, Minneapolis, MN, USA) in a 384 format using a combination of a SELMA (Jena, Germany) pipetting robot and a BioTek (Winooski, VT, USA) dispenser/washer. Absorption was read at 450 nm with wavelength correction set to 540 nm using an ELISA plate reader (Bio-Rad, Hercules, CA, USA). Intra- and inter-assay coefficients of variation were <10% for all EIAs. For immunoassays blood was drawn using EDTA vials and the plasma was isolated the next working day and stored at -80°C. As plasma samples were collected over a long period, we evaluated potential degradation by comparing CRP measured continuously during sample collection and CRP measured during the bulk analysis of the other inflammatory markers. These CRP measurements correlated strongly \( r=0.86 \) and both correlated similarly to time since sampling \( r=0.17 \). Thus, the positive and similar association with sample time for CRP measured during sample collection and during bulk analysis argue against an effect of sample degradation during storage.

**Insulin Resistance**

Plasma levels of insulin and glucose were analyzed at the Department of Medical Biochemistry, Oslo University Hospital. Insulin was analyzed at the Hormone Laboratory by radioimmunoassay (RIA) using standard methods. Glucose levels were analyzed using standardized platforms from Roche Diagnostics. We estimated insulin resistance using the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) (31). As the calculation is valid only with insulin levels <400 pmol/L, participants with higher levels were excluded \( N=11 \) patients.

Blood sampling was performed between 8 am and 11 am for most of the participants. All participants included in this study were fasting during blood collection.

**Medication**

Information on the use of prescribed medications including antipsychotics, immune modulating medication and statins used by patients was assessed by clinical interview and hospital records. "Defined daily dose" (DDD) was calculated according to the World Health Organization (WHO) principles. We calculated the individual total DDD based on antipsychotic polypharmacy. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults and provide a fixed unit of measurement independent of dosage form (http://www.whocc.no/atc_ddd_index/).

**Statistical Analyses**

All statistical analyses were done using the SPSS software package for Windows, version 25.0 (SPSS Chicago, USA). All analyses were two-tailed with a level of significance set at \( p<0.05 \). All skewed data was log-transformed prior to further analyses.

The cardio-metabolic risk was estimated using established atherogenic lipid ratios including TG/HDL and TC/HDL, with sex-dependent cut-offs established elsewhere (9, 10). Atherogenic lipid ratios were calculated, and enhanced cardio-metabolic risk was defined by (based on SI units, mmol/L): TC/HDL, male >5, female >4.5 (10); TG/HDL, male >1.53, female >1.09 (9). Differences in the proportion of individuals at risk between diagnostic groups were assessed using the chi-square test (unadjusted analysis). We then
adjusted for demographics (age, sex, BMI) in logistic regression analysis (adjusted analysis).

Differences in levels of inflammatory biomarkers between HC and diagnostic groups (i.e., SCZ and BD) were analyzed by multivariate analysis of covariance (MANCOVA) adjusting for demographics (age, sex, BMI).

Finally, in inflammatory markers that were elevated in patients (hs-CRP and MPO), the unadjusted and multivariable adjusted estimated atherogenic risk (i.e., based on lipid ratios) within the total patient population (i.e., SCZ and BD combined), and within diagnostic groups (i.e., SCZ and BD analyzed separately), were assessed using logistic regression. In these analyses, TC/HDL or TG/HDL were included as the dependent variable and hs-CRP or MPO were included as covariates in block 1 (unadjusted analysis). Further adjustments for conventional CVD risk factors; age, sex, BMI, insulin resistance, smoking, systolic blood pressure, and anti-psychotic treatment (DDD), were performed in block 2 (adjusted analysis). An example of a fully adjusted model is shown in Figure 2C.

RESULTS
Sample Characteristics
The clinical characteristics of the study population are shown in Table 1. The mean age and sex distribution in the patient group compared with HC were mainly the same when looking at the patient group as a whole. A subgroup analysis revealed that patients with BD were significantly older and more frequently female compared both to HC and patients with SCZ. The patients in general had significantly higher BMI, particularly so within SCZ. There was a higher proportion of non-European origin in patients compared to HC. The majority (78%) of patients received psychotropic drug treatment, with a higher DDD in SCZ than in BD.

Evaluation of lipids revealed a dysregulated profile with higher TC, LDL-c, and TG and lower HDL-c in the patients, and these differences were most prominent in patients with SCZ. Furthermore, patients, and in particular those with SCZ, had a higher degree of insulin resistance as estimated by HOMA-IR compared to HC (Table 1).

Pro-Atherogenic Lipid Ratios in Patients With Psychotic Disorders
To further evaluate the unfavorable lipid profile in patients with psychotic disorders, we calculated pro-atherogenic risk ratios based on lipid levels and assessed risk of CVD based on established sex-specific cut-offs. Since indirectly measured LDL is derived from TC, and since TC/HDL ratio also is an established predictor of CVD risk, we focused the analyses on TC/HDL and TG/HDL. The patient group as a whole had a markedly higher proportion with enhanced TC/HDL (26.2%) and TG/HDL (30.5%) compared to healthy controls (9.2% and 8.2% for TC/HDL and TG/HDL, respectively). The unadjusted risk for an elevated TC/HDL was 3.35 [CI 1.65–6.80], p<0.001 in patients compared to controls, which persisted in age, sex, and BMI adjusted analysis, 2.69 [CI 1.29–5.60], p=0.008. Corresponding figures for TG/HDL were 4.77 [CI 2.27–10.01], p<0.001 in unadjusted and 3.16 [CI 1.47–6.80], p=0.003 in adjusted analysis.

Figure 1 shows the distribution of these lipid ratios according to diagnosis (BD, SCZ) and sex. Increased lipid ratios compared to HC were observed in both patient groups and sexes with a higher frequency in men and in patients with SCZ. Of note, the proportion of female patients with an elevated TG/HDL ratio was higher (23%–29%) than for TC/HDL (14%–21%), while these frequencies were similar in male patients (32%–34%).

Inflammatory Markers in Patients With Psychotic Disorders
Patients as a whole were characterized by higher levels of hs-CRP (f=3.19, p=0.042) than HC in age, sex and BMI adjusted multivariate analysis of covariance (MANCOVA), shown in Table 2, with the highest levels in patients with SCZ (f=4.62, p=0.032) compared to HC. Circulating MPO as marker of neutrophil activation was markedly higher in patients; both in SCZ (f=16.01, p=7.1x10 -5) and in BD (f=11.01, p=0.001) compared to HC. In contrast, we observed lower gp130 with a similar reduction in patients with BD (f=10.04, p=0.002) and SCZ (f=7.79, p=0.005) compared to HC. A similar association was observed for Galectin 3 in SCZ (f=40.5 p=4.2x10 -10 ) and in BD (f=62.8, p=4.4x10 -14 ) compared to HC, and for Cathepsin S in SCZ (f=6.91, p=0.009), and with the lowest levels in patients with BD (f=19.91, p=1.1x10 -5), compared to HC. No significant differences were observed for PTX3, OPG, IGFBP4, and vWF, although low vWF levels were noted in patients with BD (f=5.94, p=0.015) compared to HC. Within the patient population (where smoking status was available), there were no significant difference in levels of inflammatory markers between smokers and non-smokers, except with respect to vWF where smokers had higher levels (95 AU in non-smokers vs. 108 AU in smokers, p=0.025).

Association Between MPO, hs-CRP, and Atherogenic Lipid Ratios
Odds ratios (OR) were for these analyses based on log-transformed standardized values, and represent a one standard deviation (SD) increase in the analyzed marker. Figure 2 shows unadjusted and adjusted logistic regression analysis for TC/HDL (Figure 2A) and TG/HDL (Figure 2B) ratios above the cut-off for CVD risk. Data are show for all patients and within diagnostic sub-groups (i.e., SCZ or BD).

As shown in Figure 2, unadjusted logistic regression analysis revealed a strong association between higher hs-CRP levels and CVD risk as reflected by elevated atherogenic lipid ratios, with OR 1.78 (95% CI 1.47–2.16, p<0.001) for TC/HDL (Figure 2A) and OR 1.91 (95% CI 1.58–2.30, p<0.001) for TG/HDL (Figure 2B). This association, although attenuated, remained significant in adjusted logistic regression analysis (OR 1.31 for TC/HDL and OR 1.40 for TG/HDL). Multivariable adjustment included insulin resistance (IR), smoking, anti-psychotic treatment (DDD), age, sex, BMI, hs-CRP (CRP), and MPO. The association was stronger in SCZ patients, where it remained significant in adjusted analysis with OR 1.49 (95% CI 1.14–1.96, p=0.004), while the association was not significant in BD following adjustment.
TABLE 1 | Demographics of the study population.

| Clinical parameters               | HC(n=99) | All patients(n=818) | BD(n=247) | SCZ(n=571) | Post hoc |
|-----------------------------------|----------|---------------------|-----------|------------|----------|
|                                   | % (n)    | % (n)               | % (n)     | % (n)      |          |
| Sex (male)                        | 61.6 (61)| 52.8 (432)          | 39.3 (97) | 58.7 (335) | SCZ, HC > BD |
| Ethnicity (European)              | 98.0 (97)| 82.2 (672)***       | 89.1 (220)| 79.2 (452) | HC > BD, SCZ |
| Smoking status (daily use)        | N/A      | 46.2 (367)          | 43.8 (106)| 47.3 (261) | n.s.     |
| Statin use                        | 0 (0)    | 1.7 (14)            | 2.0 (5)   | 1.6 (9)    | n.s.     |
| Anti-psychotic treatment (DDD)    | N/A      | 0.96 (0.96)         | 0.5 (0.77)| 1.13 (0.97)| SCZ > BD |
| Age                               | 30 (8)   | 31 (11)             | 34 (12)   | 30 (10)    | BD > SCZ, HC |
| Cardiometabolic risk factors      |          |                     |           |            |          |
| HOMA-IR                           | 2.7 (1.5)| 3.7 (2.6)**         | 3.4 (2.2) | 3.8 (2.7)  | SCZ > BD, HC |
| HDL-c (mmol/L)                    | 1.51 (0.46)| 1.36 (0.43)**     | 1.46 (0.48)| 1.31 (0.40)| HC > BD, SCZ |
| LDL-c (mmol/L)                    | 2.85 (0.90)| 3.14 (0.95)**     | 3.02 (0.90)| 3.19 (0.96)| SCZ > BD, HC |
| Total-c (mmol/L)                  | 4.70 (0.93)| 5.10 (1.07)**     | 5.06 (1.06)| 5.11 (1.08)| SCZ > BD, HC |
| Triglycerides (mmol/L)            | 1.04 (0.44)| 1.48 (1.10)*****  | 1.39 (1.13)| 1.49 (1.08)| SCZ > BD, HC |
| BMI                               | 23.9 (3.2)| 26.3 (5.0)*****    | 25.7 (4.4)| 26.5 (5.3)| SCZ > BD, HC |
| Symptom scores                    |          |                     |           |            |          |
| PANSS total                        | N/A      | 58 (17)             | 46 (11)   | 63 (17)    | SCZ > BD |
| CDSS total                        | N/A      | 5.5 (4.8)           | 4.8 (4.9)| 5.7 (4.8)  | SCZ > BD |
| YMRS total                        | N/A      | 4.8 (5.2)           | 3.9 (5.3)| 5.3 (5.0)  | SCZ > BD |
| GAF-S                             | N/A      | 46 (13)             | 56 (12)  | 42 (11)    | BD > SCZ |
| GAF-F                             | N/A      | 46 (12)             | 53 (13)  | 44 (11)    | BD > SCZ |

Analyzed with ANOVA for continuous variables and chi-square test for categorical variables. HC, healthy controls; BD, bipolar spectrum; SCZ, schizophrenia spectrum; n, number; DDD, defined daily dose; SD, standard deviation; HOMA-IR, homeostasis model assessment for insulin resistance; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; Total-c, total cholesterol; mmol/L, millimoles per liter; BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; YMRS, Young Mania Rating Scale; GAF-S, Global Assessment of Functioning-symptoms; GAF-F, Global Assessment of Functioning- functions; N/A, not applicable; n.s., not significant; *p<0.05 **p<0.01 ***p<0.001 vs. healthy controls.

Reponen et al. Cardiovascular Risk in Psychotic Disorders

FIGURE 1 | Increased cardiovascular risk in psychotic disorders as reflected by atherogenic lipid ratios. Distribution of the total cholesterol/high-density lipoprotein (TC/HDL) (A) and triglyceride/HDL-c (TG/HDL) (B) ratios in healthy controls, patients with bipolar disorder or schizophrenia according to sex. The pie diagram shows the number of individuals with ratios above the risk cut-off.
The association between MPO and CVD risk in patients was more modest and only present for the TC/HDL ratio with OR 1.40 (95% CI 1.12–1.76, p=0.004), but persisted after multivariable adjustment with OR 1.25 (95% CI 1.04–1.52, p=0.025). The association appeared at the same level in SCZ and BD, but was more attenuated by adjustment in BD and thus only statistically significant in SCZ in adjusted analysis OR 1.29 (95% CI 1.03–1.65, p=0.038).

As both hs-CRP and MPO were associated with increased TC/HDL, we also evaluated these markers together. Figure 2C shows that both proteins were associated with an increased TC/HDL ratio in multivariable adjusted analysis.

**DISCUSSION**

Our study, evaluating a large number of relatively young (mean age = 31 years) patients with psychotic disorders, shows that this patient group is characterized by a markedly higher CVD risk. This is reflected by a larger proportion of individuals with elevated atherogenic lipid ratios among patients with psychotic disorders compared to HC, in particular in male patients and in patients with SCZ. Plasma levels of hs-CRP, a reliable downstream marker of inflammation, and MPO, a marker of neutrophil activation and oxidative stress, were higher in patients with psychotic disorders, and independently associated with unfavorable lipid ratios in multivariable analysis adjusting for conventional CVD risk factors. These data suggest that low-grade inflammation in combination with an atherogenic lipid profile may cause increased CVD risk in patients with psychotic disorders.

Dyslipidemia has frequently been reported in patients with severe mental disorders, in both medicated and drug naïve patients (32). We demonstrated relatively stable lipid levels during longitudinal testing (5 years follow-up) in patients with schizophrenia and schizoaffective disorders suggesting that lipid abnormalities may be related to core disease mechanisms (33) in addition to antipsychotic medication (7). Regardless of cause, dyslipidemia and metabolic abnormalities are closely associated with an enhanced risk of cardiovascular outcomes. In this regard, atherogenic lipid ratios such as the TC/HDL and TG/HDL hold greater predictive value in individuals without symptomatic CVD than the independent lipid parameters (10). We were unable to find age and sex distributed reference data on the prevalence of increased ratios in the general population.

**TABLE 2** | Level of inflammatory markers (MANCOVA) after adjustment for age, BMI, and sex.

|        | HC(n=99) | All patients(n=818) | BD(n=247) | SCZ(n=571) |
|--------|----------|---------------------|-----------|------------|
| hsCRP (mg/L) | 1.78 (1.44, 2.19) | 2.18 (2.02, 2.36)* | 1.96 (1.70, 2.26) | 2.29 (2.09, 2.51)* |
| PTX3 (ng/ml)  | 2.97 (2.53, 3.49) | 3.01 (2.84, 3.19) | 3.03 (2.72, 3.37) | 3.01 (2.80, 3.23) |
| OPG (ng/ml)  | 1.32 (1.24, 1.40) | 1.35 (1.32, 1.38) | 1.36 (1.31, 1.42) | 1.35 (1.31, 1.38) |
| vWF (AU)  | 82.6 (70.8, 96.6) | 72.8 (68.5, 77) | 67.3 (60.7, 74.7)* | 75.3 (70.4, 80.7) |
| gp130 (ng/ml) | 234 (224, 243) | 217 (214, 223)** | 214 (206, 220)** | 218 (214, 222)** |
| Gal3 (mg/ml)  | 5.47 (5.56, 6.56) | 5.27 (5.05, 5.68)** | 5.23 (4.98, 5.68)** | 5.24 (5.06, 5.68)** |
| CatS (mg/ml) | 5.90 (5.57, 6.41) | 5.35 (5.19, 5.50)** | 4.99 (4.71, 5.28)** | 5.51 (5.32, 5.69)** |
| MPO (mg/ml)  | 179 (148, 218) | 275 (256, 296)** | 204 (195, 213)** | 266 (245, 290)** |
| IGFBP4 (ng/ml) | 161 (151, 170) | 165 (161, 168) | 166 (160, 173) | 164 (160, 168) |

Data are presented as estimated marginal means with 95% confidence interval. *p<0.05, **p<0.01, ***p<0.001 vs. healthy controls; fp<0.01 vs. bipolar disorder. MANCOVA, multivariate analysis of covariance; BMI, body mass index; n, number; hs-CRP, high sensitivity c-reactive protein; PTX3, pentraxin 3; OPG, osteoprotegerin; vWF, von Willebrand factor; gp130, glycoprotein 130; Gal3, galectin 3; CatS, catherine S; MPO, myeloperoxidase; IGFBP4, insulin-like growth factor-binding protein 4; mg/L, milligrams per liter; mg/mL, nanograms per milliliter; AU, arbitrary units.
However, the average TC/HDL ratio observed in healthy men and women in our study corresponded to the 50 percentile for 30-year-olds in a large contemporary population-based Dutch cohort study (34), suggesting that although limited in size the proportion of controls with increased lipid ratios in our study is comparable to similar European populations. This supports our data indicating a markedly enhanced CVD risk in this young population of patients with SCZ and BD, which may be related to the decreased life expectancy and plausibly increasing mortality due to cardiovascular causes in such patients (5, 35, 36). The higher proportion of patients with an elevated TG/HDL, compared to TC/HDL, (30.5% vs. 26.2%) in our study is compatible with the metabolic phenotype in these patients such as insulin resistance. Indeed, an increased TG/HDL ratio has been shown to closely correlate with insulin resistance in SCZ (37) as well as with the presence of small dense LDL particles which are particularly atherogenic (37, 38).

The interplay between dyslipidemia and chronic inflammation are hallmarks of atherosclerotic progression (39). CRP is the prototypical acute phase serum protein that rises rapidly in response to inflammation, but also represents the most robust marker of subclinical chronic inflammation. Chronic elevated levels have repeatedly been associated with persistent auto-inflammatory processes and an increased risk of future cardiovascular events in the general population (14, 40), and with CVD risk in patients with psychotic disorders (41–44). Our finding that elevated hs-CRP was associated with CVD risk as reflected by the TC/HDL and TG/HDL also in adjusted analysis including important cardio-metabolic risk factors, support these previous studies. Furthermore, this association was stronger and only significant after full multivariable adjustment in SCZ suggesting a stronger impact of inflammatory dysregulation on CVD risk in these patients. However, although hs-CRP by reflecting the general inflammatory burden related to important demographics such as insulin resistance and BMI (45, 46) represents a reliable risk marker of CVD, it is less useful in pinpointing specific dysregulation of inflammation that may be linked to CVD risk.

A major finding in our study was the markedly increased MPO levels in both SCZ and BD that were significantly associated with the TC/HDL ratio, also in adjusted analysis for SCZ. MPO is a reliable marker of neutrophil activation. These cells have recently received renewed interest with regard to atherosclerosis due to the variety of active substances they may release from granules, including reactive oxygen species promoting oxidation of lipoproteins, micro particles, and MPO that further are related to neutrophil extracellular traps (NETs). Aberrant neutrophil effector functions and increased circulating levels of inflammatory neutrophil effector peptides, such as alpha-defensins have been linked to SCZ pathogenesis (47) and may represent a bridging factor between neutrophil effector peptides, such as alpha-defensins have been linked to SCZ pathogenesis (47) and may represent a bridging factor between neutrophil extracellular traps (NETs). Aberrant neutrophil oxidation of lipoproteins, microparticles, and MPO that further are linked to vascular inflammation and CVD such as vWF (18), OPG (17), PTX3 (16), while levels of fibrosis and ECM remodeling markers such as Galectin 3 (19) and Cathepsin S (20) were lower, which may further support our hypothesis regarding dysregulated neutrophil effector functions and a consequent low-grade inflammatory “background”. These markers have repeatedly been associated with risk of adverse cardiovascular outcomes, but have mainly been investigated in patients with stable atherosclerotic disease. However, the association with CVD risk in patients without established CVD may be different than in patients with symptomatic CVD concerning both the strength and potentially the direction of association (54). Based on the relatively young age of our population, vascular inflammation and ECM remodeling, which accelerate during atherogenesis, may not yet be activated. However, we are not able to conclude with respect to this without following the same patient group over time.

**LIMITATIONS**

This study had a cross-sectional design, making the causality described suggestive. As fasting status can affect levels of the inflammatory markers, glucose, and lipid metabolism, we focused this study on fasting blood samples. This excluded 435 non-fasting controls and limited our control population to n=99, and gave uneven group size compared to the patient population (n=818). The relatively high portion of non-fasting participants in the initial control group was mostly due to their busy everyday lives, making it challenging to schedule blood sampling in the morning. These controls are used in other studies performed by the group. Furthermore, looking at differences between our patient group and HC, the majority of the healthy controls in the current sample are young and well-functioning, with a lower BMI than the patients, possibly underestimating the impact of lifestyle factors on dysregulation of some inflammatory markers. The smoking status is not available for our healthy controls. However, comparing inflammatory markers within the patient population, only vWF was significantly affected with higher levels in smokers. Also, while the effect of smoking on inflammation is less documented, the effect of smoking on CVD risk is known. Therefore, since we had smoking status in our patients, we were able to adjust for smoking when evaluating CVD risk. Future studies should include control groups that are better matched with the patient group in regard to their metabolic status. Finally, in our study, only 14 patients were using lipid-lowering agents, thus our sample was statistically underpowered to address the issue if these agents can be used as an early intervention to reduce CVD risk.
CONCLUSION

Patients with psychotic disorders have a markedly higher CVD risk compared to healthy controls as reflected by atherogenic lipid ratios, and the increased risk is associated with elevated hs-CRP and MPO reflecting subclinical inflammation and abnormal neutrophil activation in such patients. These findings support that low-grade inflammation may cause increased CVD risk in patients with psychotic disorders. These mechanisms should be further examined to determine the potential for treatment targets or development of novel risk evaluation strategies.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because sharing of data to external parties has not been approved by the ethics committee. Requests to access the datasets should be directed to e.j.reponen@medisin.uio.no.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Regional komite for medisinsk forskningsetikk, Øst-Norge (REK 1). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors contributed to the article and approved the submitted version. Each author specifically made the following contributions to this manuscript: ER: Data collection, literature search, statistical analysis, and manuscript editing. ID: Data collection, literature search, statistical analysis, and manuscript editing. MT: Data collection, literature search, statistical analysis, and manuscript editing. RM: Data collection, statistical analysis, and manuscript editing. MA: Data collection, statistical analysis, and manuscript editing. TV: Data collection and manuscript editing. EH: Data collection and manuscript editing. OD: Data collection and manuscript editing. NS: Data collection and manuscript editing. SH: Data collection, literature search, and manuscript editing. AS: Literature search and manuscript editing. SMG: Literature search and manuscript editing. KW-R: Literature search and manuscript editing. SD: Data collection, literature search, and manuscript editing. IM: Data collection and manuscript editing. PA: Data collection, literature search, and manuscript editing. OA: Data collection, literature search, statistical analysis, and manuscript editing. TU: Data collection, literature search, statistical analysis, and manuscript editing.

FUNDING

This work was supported by the Research Council of Norway (grant numbers 213837, 223273, 217776), the South-Eastern (grant numbers 2017-112, 2016-064) and Western (grant number 91141) Norway Regional Health Authorities, and the KG Jebsen Stiftelsen (grant number SKGJ-2011-36).

ACKNOWLEDGMENTS

The authors would like to thank the participants of the study for their contribution. We also wish to thank the Department of Medical Biochemistry, Oslo University Hospital and professor Karin Toska for their contribution.

The results of the preliminary analysis of this study with the same title “Atherogenic Lipid Ratios Related to Myeloperoxidase and C-reactive Protein Levels in Psychotic Disorders” (Elina J. Reponen et al.), were presented at the poster session (T8) at the 2019 Congress of the Schizophrenia International Research Society, Orlando, Florida, USA (55). We would like to acknowledge the Schizophrenia International Research Society for their contribution.

REFERENCES

1. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull (2013) 39(2):306–18. doi: 10.1093/schbul/sbr148

2. Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialog Clin Neurosci (2018) 20(1):63–73.

3. Laursen TM, Wahlbeck K, Hallgren J, Westman J, Osby U, Ailionghiaedeh H, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One (2013) 8(6):e67133. doi: 10.1371/journal.pone.0067133

4. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry (2017) 211:175–81. doi: 10.1192/bjp.bp.117.202606

5. Pietrowksi P, Gondek TM, Krolicka-Deregowsa A, Misiaik B, Adamowski T, Kieja A. Causes of mortality in schizophrenia: An updated review of European studies. Psychiatr Danubina (2017) 29(2):108–20. doi: 10.24869/pdyd.2017.108

6. Heiberg IH, Jacobsen BK, Balteskard L, Branneby JG, Naess O, Ystrem E, et al. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand (2019) 139(6):558–71. doi: 10.1111/acps.13017

7. Abosi O, Lopes S, Schmitz S, Fidorowicz JG. Cardiometabolic effects of psychotropic medications. Hormone Mol Biol Clin Invest (2018) 36(1):1–15. doi: 10.1515/hmbci-2017-0065

8. Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med (2017) 47(3):2217–28. doi: 10.1017/S0033291717000873

9. Salazar MR, Carbajal HA, Espeche WG, Leiva Sinuguece CE, Balbin E, Dulbecco CA, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol (2012) 109(12):1749–53. doi: 10.1016/j.amjcard.2012.02.016

10. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manage (2009) 5:757–65. doi: 10.2147/VHRM.S6269
comorbid cardiometabolic disease risk factors. *Psychol Med* (2019) 49 (10):1749–57. doi: 10.1017/S0033291718004142

31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* (2004) 27(6):1487–95.

32. Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. *Schizophr Res* (2017) 190:18–27. doi: 10.1016/j.schres.2017.03.031

33. Solberg DK, Bentsen H, Refsum H, Andreassen OA. Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study. *BMJ Psychiatry* (2016) 16299. doi: 10.1186/s12888-016-1006-3

34. Balder JW, de Vries JK, Nolte IM, Lansberg PJ, Kuijvenhoven JA, Kamphuisen PW. Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles. *J Clin Lipidol* (2017) 11(4):1055–64.e6. doi: 10.1016/j.jacl.2017.05.007

35. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. *Front Psychiatry* (2014) 5:137. doi: 10.3389/fpsyt.2014.00137

36. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. *Ann Clin Psychiatry* (2011) 23(1):40–7.

37. Pan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, Henderson DC. Triglyceride/ high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nonobese patients with schizophrenia. *J Clin Psychiatry* (2011) 72(6):806–12. doi: 10.4088/JCP.09m05107vel

38. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *Jama* (1996) 276(11):875–81. doi: 10.1001/jama.276.11.875

39. Gistera A, Hansson GK. The immunology of atherosclerosis. *Nat Rev Nephrol* (2017) 13(6):368–80. doi: 10.1038/nrneph.2017.51

40. Albert CM, Ma J, Rifiati N, Stampler MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* (2002) 105(22):2595–9. doi: 10.1161/01.CIR.000004793.03108.1C

41. Wysocki A, Margulsa A, Strzelecki D, Kloszewsa I. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. *Nordic J Psychiatry* (2015) 69(5):346–53. doi: 10.3109/08039488.2014.947575

42. Joshi KB, Nillawar A, Thorat AP. Cardiovascular disease risk in schizophrenia patients: a case control study. *J Clin Diag Res* (2013) 7(12):2694–6. doi: 10.7860/JCDR/2013/7592.3734

43. Miller B, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. *Circulation Related Psychoses* (2014) 7(4):223–30. doi: 10.3371/CRSP.MICU.020813

44. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R, Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. *Eur Psychiatry* (2013) 28(3):161–7. doi: 10.1016/j.eurpsy.2011.07.003

45. Festa A, D’Agostino R Jr, Howard G, Mykkkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* (2000) 102(1):42–7. doi: 10.1161/01.CIR.102.1.42

46. Yucel-Cusa B, Sagul M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, et al. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. *Nordic J Psychiatry* (2013) 67(5):320–5. doi: 10.3109/08039488.2012.745601

47. Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M, et al. Increased alpha-defensins as a blood marker for schizophrenia susceptibility. *Mol Cell Proteomics* (2008) 7(7):1204–13. doi: 10.1074/mcp.M700459-MCP200

48. Maneerat Y, Prasongsukarn K, Benjahumarak S, Dechkhajorn W, Chaisri U. Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients. *Lipids Health Dis* (2016) 15(117):117. doi: 10.1186/s12944-016-0285-5
49. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation* (2003) 108(12):1440–5. doi: 10.1161/01.CIR.0000096690.67322.51

50. Meuwese MC, Stroes ES, Hazen SL, van Miert IN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. *J Am Coll Cardiol* (2007) 50(2):159–65. doi: 10.1016/j.jacc.2007.03.033

51. Munkholm K, Jacoby AS, Lenskjold T, Bruunsgaard H, Vinberg M, Kessing LV. Leukocytes in peripheral blood in patients with bipolar disorder - Trait and state alterations and association with levels of cytokines and C-reactive protein. *Psychiatry Res* (2018) 261:383–90. doi: 10.1016/j.psychres.2018.01.022

52. Mazzu MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* (2018) 84(Pt A):229–36. doi: 10.1016/j.pnpbp.2018.03.012

53. Ozdin S, Sarisoy G, Boke O. A comparison of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in schizophrenia and bipolar disorder patients - a retrospective file review. *Nordic J Psychiatry* (2017) 71(7):509–12. doi: 10.1080/08039488.2017.1340517

54. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. *Jama* (2011) 305(8):822–3. doi: 10.1001/jama.2011.163

55. Reponen E, Dieset I, Tesli M, March RH, Steen NE, Hope S, et al. Atherogenic Lipid Ratios Related to Myeloperoxidase and C-reactive Protein Levels in Psychotic Disorders. *Schizophr Bull* (2019) 45(Supplement_2):S206–S. doi: 10.1093/schbul/sbz019.288

**Conflict of Interest:** OA and RM have received speaker’s honorarium from Lundbeck. OA is consultant to HealthLytx.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Reponen, Dieset, Tesli, March, Aas, Vedal, Haug, Oranje, Steen, Hope, Szabo, Gohar, Wedervang-Resell, Djurovic, Melle, Aukrust, Andreassen and Ueland. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*